MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-B2 Signaling Pathway

Background: Mantle cell lymphoma (MCL) is an aggressive malignancy that accounts for 5-10% of non-Hodgkin's lymphoma. MiRNA-223-3p has been demonstrated to be downregulated in MCL and is a useful prognostic factor. However, little is known about underlying molecular mechanism of miRNA-233-3p in MCL. Methods: The expression levels of miRNA-223-3p and CHUK mRNA in MCL cells were detected by real-time quantitative PCR (RT-qPCR). The effects of miRNA-223-3p/CHUK overexpression/knockdown on MCL cell proliferation and apoptosis were measured by CCK-8 assay and annexin V PE/7-AAD-based flow cytometry/TUNEL assay, respectively. A nude mouse subcutaneous xenograft model was used to further evaluate the potential effects in vivo. Dual-luciferase reporter assay was used to verify the inhibitory effect of miRNA-223-3p on CHUK. Furthermore, the regulatory function of miRNA-223-3p on the CHUK/NF-kappa B2 axis was assessed by RT-qPCR, western blot and immunofluorescence. Results: In the present study, miRNA-223-3p overexpression inhibited proliferation and accelerated apoptosis of MCL cells in vitro and in vivo. The results of Luciferase reporter assay showed that CHUK was a direct target of miRNA-223-3p in HEK293T cells. Furthermore, the results of RT-qPCR, western blot confirmed that CHUK was targeted and negatively regulated by miRNA-223-3p for repressing NF-kappa B2 pathway activation in MCL cells. Importantly, CHUK overexpression promoted proliferation and suppressed apoptosis of MCL cells, whereas CHUK knockdown reversed down-regulated miRNA-223-3p -accelerated cell proliferation in vitro. Conclusion: In conclusion, miRNA-223-3p affects MCL development by regulating the CHUK/NF-kappa B2 signaling pathway, which is crucial to provide a novel therapeutic strategy.